Literature DB >> 19156656

Synthesis, characterization, cytotoxicity, and hydrolytic behavior of C2- and C1-symmetrical Ti(IV) complexes of tetradentate diamine bis(phenolato) ligands: a new class of antitumor agents.

Dani Peri1, Sigalit Meker, Michal Shavit, Edit Y Tshuva.   

Abstract

We recently introduced a new class of bis(isopropoxo)-Ti(IV) complexes with diamine bis(phenolato) ligands that possess antitumor activity against colon HT-29 and ovarian OVCAR-1 cells that is higher than that of the known Ti(IV) compounds titanocene dichloride and budotitane as well as that of cisplatin. Herein, we elaborate on this family of compounds; we discuss the effect of structural parameters on the cytotoxic activity and hydrolytic behavior of these complexes, seeking a relationship between the two. Whereas complexes with small steric groups around the metal center possess high activity and lead mostly to formation of O-bridged polynuclear complexes with bound bis(phenolato) ligand upon water addition, bulky complexes hydrolyze to release all free ligands and are inactive. Slightly increasing the size of the N-donor substituents probably weakens the ligand binding in solution, and, thus, rapid hydrolysis is observed, leading to a lack of cytotoxicity, supporting the requirement for ligand inertness. Replacing the two isopropoxo ligands with a single catecholato unit gives a complex with a different geometry that exhibits slower hydrolysis and reduced cytotoxicity, suggesting some participation of labile ligand hydrolysis in the cytotoxicity mechanism. A crystallographically characterized O-bridged polynuclear species obtained from a biologically active bis(isopropoxo) complex upon water addition is inactive, which rules out its participation as the active species, yet suggests some role of the particular steric and electronic requirements allowing its formation in the activity mechanism. Additional measurements support rapid formation of the active species in the presence of cells prior to O-bridged Ti(IV) cluster formation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19156656     DOI: 10.1002/chem.200801310

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  6 in total

1.  Expanding the Therapeutic Potential of the Iron Chelator Deferasirox in the Development of Aqueous Stable Ti(IV) Anticancer Complexes.

Authors:  Sergio A Loza-Rosas; Alexandra M Vázquez-Salgado; Kennett I Rivero; Lenny J Negrón; Yamixa Delgado; Josué A Benjamín-Rivera; Angel L Vázquez-Maldonado; Timothy B Parks; Charlene Munet-Colón; Arthur D Tinoco
Journal:  Inorg Chem       Date:  2017-06-23       Impact factor: 5.165

2.  Synthesis of asymmetrical diaminobis(alkoxo)-bisphenol compounds and their C1-symmetrical mono-ligated titanium(iv) complexes as highly stable highly active antitumor compounds.

Authors:  Gilad Nahari; Edit Y Tshuva
Journal:  Dalton Trans       Date:  2021-05-04       Impact factor: 4.390

3.  The elements of life and medicines.

Authors:  Prinessa Chellan; Peter J Sadler
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2015-03-13       Impact factor: 4.226

4.  Synthesis of Pure Enantiomers of Titanium(IV) Complexes with Chiral Diaminobis(phenolato) Ligands and Their Biological Reactivity.

Authors:  Maya Miller; Edit Y Tshuva
Journal:  Sci Rep       Date:  2018-06-26       Impact factor: 4.379

5.  Titanium Tackles the Endoplasmic Reticulum: A First Genomic Study on a Titanium Anticancer Metallodrug.

Authors:  Maya Miller; Anna Mellul; Maya Braun; Dana Sherill-Rofe; Emiliano Cohen; Zohar Shpilt; Irene Unterman; Ori Braitbard; Jacob Hochman; Edit Y Tshuva; Yuval Tabach
Journal:  iScience       Date:  2020-06-12

6.  Racemic vs. enantiopure inert Ti(iv) complex of a single diaminotetrakis(phenolato) ligand in anticancer activity toward human drug-sensitive and -resistant cancer cell lines.

Authors:  Maya Miller; Edit Y Tshuva
Journal:  RSC Adv       Date:  2018-11-27       Impact factor: 4.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.